CYP11B2

Laekna, a Biotechnology Company in China, Listed on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
Thursday, June 29, 2023
IIA, Stock exchange, Bimagrumab, Prednisone, Sintilimab, Patient, Investment, Federal Medical Centres, Mab, Cornerstone, Prostate cancer, Biomedical Research, Clinical trial, Hepatic stellate cell, Research, Motherboard, Drug discovery, Knowledge, FDA, IND, Frost, Cirrhosis, Global Health Innovative Technology Fund, International, Biotechnology, Cancer, Breakthrough therapy, AKT, Core product, CYP17A1, CYP11B2, Social responsibility, Drug development, Liver disease, ATP, Drug resistance, Trust, Limited partnership, Multi, Hong Kong Stock Exchange, SCGC, HK, Management, Pharmaceutical industry, IPO, Novartis

HONG KONG, June 29, 2023 - (ACN Newswire) - A biotechnology company in China - Laekna, Inc. (stock code: 2105.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").

Key Points: 
  • HONG KONG, June 29, 2023 - (ACN Newswire) - A biotechnology company in China - Laekna, Inc. (stock code: 2105.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").
  • (2) Use for advancing the clinical development and approval of the other Core Product of the Company, LAE002.
  • The Hong Kong Offering also recorded an over-subscription, of approximately 5.81 times of the 6,373,000 shares offered.
  • The Company has established a number of global and regional partnerships with leading pharmaceutical companies, including Novartis and Innovent.

Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value

Retrieved on: 
Monday, July 25, 2022
Newton, Sale, ROCK2, GLOBE, U.S. Securities and Exchange Commission, CYP11B2, Private Securities Litigation Reform Act, Fibrosis, Board, COVID-19, NASDAQ, Director, Oppenheimer, Board of directors, Security (finance), Therapy, Pharmaceutical industry

Angions Board of Directors has approved engagement of Oppenheimer & Co., Inc. as the companys exclusive financial advisor to assist in this process.

Key Points: 
  • Angions Board of Directors has approved engagement of Oppenheimer & Co., Inc. as the companys exclusive financial advisor to assist in this process.
  • Potential strategic options to be explored or evaluated as part of this process may include, but are not limited to, merger, reverse merger, other business combination, sale of assets, licensing, or other strategic transactions involving Angion.
  • Angion does not expect to disclose developments with respect to this process unless until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.
  • Angions management and Board of Directors have moved quickly begin exploring strategic alternatives as the best option for enhancing and preserving shareholder value, stated Dr. Jay Venkatesan, Angions President and Chief Executive Officer.

Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

Retrieved on: 
Wednesday, June 29, 2022
CYP11B2, FSGS, Patient, IPF, GLOBE, COVID-19, U.S. Securities and Exchange Commission, Kidney, Idiopathic pulmonary fibrosis, Therapy, Private Securities Litigation Reform Act, IgA nephropathy, TKI, Proteinuria, Focal segmental glomerulosclerosis, NASDAQ, ROCK2, Safety, Security (finance), Pharmaceutical industry

These factors collectively lead Angion to believe discontinuation of the JUNIPER study is in the best interest of patients.

Key Points: 
  • These factors collectively lead Angion to believe discontinuation of the JUNIPER study is in the best interest of patients.
  • Angion is communicating with clinical trial sites and regulatory authorities regarding its decision to terminate the trial.
  • We are, of course, disappointed by todays announcement and have made the decision to deprioritize the study of ANG-3070 in patients with established serious kidney disease.
  • A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is planned to start in 2022.

DGAP-News: Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension

Retrieved on: 
Wednesday, June 8, 2022
HBM, Company, Plasma, Investment, Lists of publishing companies, Hormone, RA, News, Partnership, Capital, Development, Diagnosis, Andera-ye Olya, Industry, Heart, Aldosterone, MPH, Hypertension, Chronic kidney disease, Series, Partner, Patient, Mitsubishi Tanabe Pharma, Blood pressure, DGAP, CYP11B2, RTW, Therapy, Growth, Board, Pharmaceutical industry, Security (finance), Medical device, Financial services, Doctor of Philosophy

Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension

Key Points: 
  • Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension
    The issuer is solely responsible for the content of this announcement.
  • Existing investors, including founding investment firm Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments and Adams Street Partners also participated.
  • As part of the Series B financing, Derek DiRocco, Partner, RA Capital Management and Olivier Litzka, PhD, Partner, Andrea Partners will join the Mineralys Board of Directors.
  • The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101.

Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022
Income, Private Securities Litigation Reform Act, Food, Research, U.S. Securities and Exchange Commission, Cardiopulmonary bypass, FSGS, Patient, NASDAQ, Vifor Pharma, ROCK2, CYP11B2, Â, COVID-19, Kidney, FDA, IND, CRO, Safety, Degenerative disease, IPO, Therapy, CMO, DGF, Idiopathic pulmonary fibrosis, IPF, Security (finance), Investigational New Drug, GLOBE, Fine chemical, Pharmaceutical industry, IgA nephropathy

UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended March 31, 2022.

Key Points: 
  • UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended March31, 2022.
  • As of March31, 2022, Angion had cash and cash equivalents totaling $73.0 million.
  • Contract revenue for the quarter ended March31, 2022 was $1.6 million compared with $0.4 million in the same period in 2021.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Retrieved on: 
Monday, May 16, 2022
Epithelium, DDR1, Fibroblast, Private Securities Litigation Reform Act, Food, Survival, U.S. Securities and Exchange Commission, Patient, NASDAQ, ROCK2, CYP11B2, Prescription, COVID-19, PDGF, Cell, Kidney, FDA, IND, DDR2, Plasma, Fibrosis, Safety, Pathology, Degenerative disease, Lung, Therapy, Security (finance), Idiopathic pulmonary fibrosis, IPF, PK, Arm, Investigational New Drug, GLOBE, Pharmaceutical industry, Vaccine

UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug Administration’s (FDA) acceptance of an Investigational New Drug (IND) application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis (IPF) and clearance to begin a Phase 1b study of ANG-3070 in patients with IPF.

Key Points: 
  • IPF patients eligible for this Phase 1b study of ANG-3070 include those who have discontinued nintedanib or pirfenidone, refused treatment with nintedanib or pirfenidone, or those who are treatment nave.
  • Approximately 20 IPF patients will be enrolled into a crossover design trial with four arms dosing for ten days each.
  • A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is targeted to enroll and report data in 2022.
  • A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is targeted to enroll and report data in 2022.

Angion Announces Participation in Upcoming Investment Conference

Retrieved on: 
Thursday, May 12, 2022
Webcast, Patient, NASDAQ, ROCK2, CYP11B2, Conference, Degenerative disease, Therapy, GLOBE, CEO, Pharmaceutical industry

UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.

Key Points: 
  • UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.
  • Angions President and CEO, Dr. Jay Venkatesan, will participate virtually in the H.C. Wainwright Global Investment Conference.
  • Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known limitations.
  • Additionally, Angion has preclinical programs focused on rho kinase 2 (ROCK2) inhibition and CYP11B2 (aldosterone synthase) inhibition.

Angion Announces Participation in Upcoming Investment Conference

Retrieved on: 
Thursday, April 14, 2022
CEO, NASDAQ, GLOBE, Patient, CYP11B2, Conference, Webcast, Degenerative disease, ROCK2, Therapy, Pharmaceutical industry

UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.

Key Points: 
  • UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.
  • Angions President and CEO, Dr. Jay Venkatesan, will participate in the Shareholder Equity Conference, held virtually.
  • The presentation will be a fireside chat format and investors will have the opportunity to ask management questions during the live presentation.
  • Additionally, Angion has preclinical programs focused on rho kinase 2 (ROCK2) inhibition and CYP11B2 (aldosterone synthase) inhibition.

Angion Provides Corporate Update and Reports Full Year 2021 Financial Results

Retrieved on: 
Wednesday, March 30, 2022
Department of Defense Architecture Framework, Private Securities Litigation Reform Act, Risk, Idiopathic pulmonary fibrosis, Population, NASDAQ, Therapy, Acute kidney injury, DOD, Event, Patient, IND, Research, FSGS, Conference, Vifor Pharma, Cardiopulmonary bypass, AKI, Immunoglobulin A, DGF, U.S. Securities and Exchange Commission, IPF, Glomerulosclerosis, Safety, ROCK2, Society, CYP11B2, COVID-19, GLOBE, Degenerative disease, Department, Accounting, IPO, Security (finance), Pharmaceutical industry, Cryptocurrency, IgA nephropathy

UNIONDALE, N.Y., March 30, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today reported its financial results for full year 2021.

Key Points: 
  • While neither trial achieved statistical significance on its primary endpoint, Angion believes ANG-3777 demonstrated biologic activity in both trials.
  • Angion continues to work with its partner Vifor Pharma on the process of closing out its analyses of data from these trials.
  • As of December 31, 2021, Angion had cash and cash equivalents totaling $88.8 million.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Mineralys Therapeutics Appoints Adam Levy as Chief Financial Officer and Chief Business Officer

Retrieved on: 
Tuesday, March 15, 2022
Therapy, Wedbush Securities, Jefferies Group, Blood pressure, Chronic kidney disease, Patient, Merrill Lynch, Pierce, Fenner & Smith, Inc. v. Dabit, Plasma, Nasdaq, Hormone, CFO, Aldosterone, Hypertension, CBO, Company, Mitsubishi Tanabe Pharma, CYP11B2, Merrill (company), Industry, Vifor Pharma, Pharmaceutical industry

PHILADELPHIA, March 15, 2022 /PRNewswire/ -- Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension, today announced the appointment of Adam Levy as the company's new Chief Financial Officer (CFO) and Chief Business Officer (CBO).

Key Points: 
  • PHILADELPHIA, March 15, 2022 /PRNewswire/ -- Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension, today announced the appointment of Adam Levy as the company's new Chief Financial Officer (CFO) and Chief Business Officer (CBO).
  • "We are pleased to announce Adam's appointment and welcome him to the Mineralys leadership team.
  • Adam brings more than two decades of operational and transactional expertise in biotech and investment banking.
  • As CBO at miRagen Therapeutics, Inc., Adam had broad operational responsibilities and led several business development transactions and capital raises, including a listing on the Nasdaq.